Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase

Targeted Oncology

Volumn 9, Issue 3, 2014, Pages 279-286

  Fan, Huijin ^a,b   Tian, Weixi ^a   Ma, Xiaofeng ^a  

^a UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^b NATIONAL RESEARCH INSTITUTE FOR FAMILY PLANNING   (China)

Author keywords

Cell apoptosis; Curcumin; Fatty acid synthase; HepG2 cells; Inhibitor

Indexed keywords

EID: 84879477017     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0286-5     Document Type: Article

References (39)

1. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763–77
2. Mashima T, Seimiya H, Tsuruo T (2009) De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Brit J Cancer 100:1369–72
3. Rossi S, Ou W, Tang D et al (2006) Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol 209:369–75
4. Flavin R, Peluso S, Lnguyen P (2010) Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6:551–62
5. Kuhajda FP, Pizer ES, Li JN et al (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. P Natl Acad Sci USA 97:3450–4
6. Alò PL, Visca P, Trombetta G et al (1999) Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85:35–40
7. Gansler TS, Hardman W, Hunt DA et al (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28:686–92
8. Innocenzi D, Alò PL, Balzani A et al (2003) Fatty acid synthase expression in melanoma. J Cutan Pathol 30:23–8
9. Rashid A, Pizer ES, Moga M et al (1997) Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150:201–8
10. Sekiguchi M, Shiroko Y, Arai T et al (2001) Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines. Biomed Pharmacother 55:466–74
11. Brusselmans K, De Schrijver E, Heyns W et al (2003) Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 106:856–862
12. Menendez JA, Lupu R (2004) Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp 52:414–26
13. Puig T, Vázquez-Martín A, Relat J et al (2008) Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 109:471–9
14. Braga ME, Leal PF, Carvalho JE et al (2002) Comparison of yield, composition, and antioxidant activity of turmeric (Curcuma longa L.) extracts obtained using various techniques. J Agric Food Chem 51:6604–11
15. Khor TO, Keum YS, Lin W et al (2006) Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immune deficient mice. Cancer Res 66:613–21
16. Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199–225
17. Kunnumakkara AB, Guha S, Krishnan S et al (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB regulated gene products. Cancer Res 67:3853–61
18. Ravindran J, Prasad S, Aggarwal BB (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11:495–510
19. Wu SH, Hang LW, Yang JS et al (2010) Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade and mitochondria-dependent pathways. Anticancer Res 30:2125–33
20. Xu Y, Zhang J, Han J et al (2012) Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of α1-antitrypsin in lung cancer. Mol Oncol 6:405–17
21. Ruby AJ, Kuttan G, Babu KD et al (1995) Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94:79–83
22. Kumar V, Lewis SA, Mutalik S et al (2002) Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 46:209–17
23. Zhao J, Sun X, Ye F et al (2011) Suppression of fatty acid synthase, differentiation and lipid accumulation in adipocytes by curcumin. Mol Cell Biochem 351:19–28
24. Wang X, Tian W (2001) Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun 288:1200–6
25. Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–421
26. Milgraum LZ, Witters LA, Pasternack GR et al (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in-situ breast carcinoma. Clin Cancer Res 3:2115–20
27. Choi WI, Jeon BN, Park H et al (2008) Proto oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J Biol Chem 283:29341–54
28. Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66:5977–80
29. Bandyopadhyay S, Pai SK, Watabe M et al (2005) FAS expression inversely correlates with PTEN level in prostate cancer and a PI3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24:5389–95
30. Radhakrishna PG, Srivastava AS, Hassanein TI et al (2004) Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 208:163–70
31. Atcher H, Planalp R, Cho J et al (2008) Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci 65:1631–52
32. Ströfer M, Jelkmann W, Depping R (2011) Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlenther Onkol 187:393–400
33. Aggarwal S, Ichikawa H, Takada Y et al (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaB alpha kinase and Akt activation. Mol Pharmacol 69:195–206
34. Lin JK (2007) Molecular targets of curcumin. Adv Exp Med Biol 595:227–43
35. Pan MH, Lin-Shiau SY, Lin JK (2000) Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 60:1665–76
36. Patel BB, Sengupta R, Qazi S et al (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122:267–73
37. Cheng AL, Hsu CH, Lin JK et al (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895–900
38. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as “curecumin”: from kitchen to clinic. Biochem Pharmacol 75:787–809
39. Pizer ES, Wood FD, Heine HS et al (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189–93